Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia

Summary Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different...

Full description

Saved in:
Bibliographic Details
Published in:Memo - Magazine of European medical oncology 2017-09, Vol.10 (3), p.164-169
Main Authors: Kavianpour, Maria, Ketabchi, Neda, Saki, Najmaldin
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203
cites cdi_FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203
container_end_page 169
container_issue 3
container_start_page 164
container_title Memo - Magazine of European medical oncology
container_volume 10
creator Kavianpour, Maria
Ketabchi, Neda
Saki, Najmaldin
description Summary Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukemia, myeloid markers (CD13 and CD33) are frequent but CD117 is rare. On the other hand, the presence of multiple translocations is also associated with a higher or lower level of aberrant markers that could be effective in changing the prognosis of patients. Further studies are needed to confirm the relationship between aberrant expression with prognosis and response to treatment of ALL.
doi_str_mv 10.1007/s12254-017-0324-6
format article
fullrecord <record><control><sourceid>crossref_sprin</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s12254_017_0324_6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1007_s12254_017_0324_6</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWKs_wFv-wOokm03So9RPKOhBb0LIZic17TYpyRb037u14tHTDMM8Ly8PIZcMrhiAui6M80ZUwFQFNReVPCITpmVTNaDk8d8u2Ck5K2UFIDkoPSHvLzktYypDcLSEZQw-OBsd0uSpbTFnGweKn9uMpYQU9-f5Ld3YvMZcaIjUut2AtP_abD9S29ufoB53a9wEe05OvO0LXvzOKXm7v3udP1aL54en-c2iclzroWK206KxDW8FZ9gKAd4q2XipQeiZE-gRuG1nNbed0op1tu5aVnMuoJMzDvWUsEOuy6mUjN5scxg7fhkGZq_HHPSYUY_Z6zFyZPiBKeNvXGI2q7TLcaz5D_QN3j1pFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia</title><source>Springer Nature</source><creator>Kavianpour, Maria ; Ketabchi, Neda ; Saki, Najmaldin</creator><creatorcontrib>Kavianpour, Maria ; Ketabchi, Neda ; Saki, Najmaldin</creatorcontrib><description>Summary Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukemia, myeloid markers (CD13 and CD33) are frequent but CD117 is rare. On the other hand, the presence of multiple translocations is also associated with a higher or lower level of aberrant markers that could be effective in changing the prognosis of patients. Further studies are needed to confirm the relationship between aberrant expression with prognosis and response to treatment of ALL.</description><identifier>ISSN: 1865-5041</identifier><identifier>EISSN: 1865-5076</identifier><identifier>DOI: 10.1007/s12254-017-0324-6</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Medicine ; Medicine &amp; Public Health ; Oncology ; Review</subject><ispartof>Memo - Magazine of European medical oncology, 2017-09, Vol.10 (3), p.164-169</ispartof><rights>Springer-Verlag Wien 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203</citedby><cites>FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Kavianpour, Maria</creatorcontrib><creatorcontrib>Ketabchi, Neda</creatorcontrib><creatorcontrib>Saki, Najmaldin</creatorcontrib><title>Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia</title><title>Memo - Magazine of European medical oncology</title><addtitle>memo</addtitle><description>Summary Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukemia, myeloid markers (CD13 and CD33) are frequent but CD117 is rare. On the other hand, the presence of multiple translocations is also associated with a higher or lower level of aberrant markers that could be effective in changing the prognosis of patients. Further studies are needed to confirm the relationship between aberrant expression with prognosis and response to treatment of ALL.</description><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Review</subject><issn>1865-5041</issn><issn>1865-5076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoWKs_wFv-wOokm03So9RPKOhBb0LIZic17TYpyRb037u14tHTDMM8Ly8PIZcMrhiAui6M80ZUwFQFNReVPCITpmVTNaDk8d8u2Ck5K2UFIDkoPSHvLzktYypDcLSEZQw-OBsd0uSpbTFnGweKn9uMpYQU9-f5Ld3YvMZcaIjUut2AtP_abD9S29ufoB53a9wEe05OvO0LXvzOKXm7v3udP1aL54en-c2iclzroWK206KxDW8FZ9gKAd4q2XipQeiZE-gRuG1nNbed0op1tu5aVnMuoJMzDvWUsEOuy6mUjN5scxg7fhkGZq_HHPSYUY_Z6zFyZPiBKeNvXGI2q7TLcaz5D_QN3j1pFw</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Kavianpour, Maria</creator><creator>Ketabchi, Neda</creator><creator>Saki, Najmaldin</creator><general>Springer Vienna</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170901</creationdate><title>Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia</title><author>Kavianpour, Maria ; Ketabchi, Neda ; Saki, Najmaldin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kavianpour, Maria</creatorcontrib><creatorcontrib>Ketabchi, Neda</creatorcontrib><creatorcontrib>Saki, Najmaldin</creatorcontrib><collection>CrossRef</collection><jtitle>Memo - Magazine of European medical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kavianpour, Maria</au><au>Ketabchi, Neda</au><au>Saki, Najmaldin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia</atitle><jtitle>Memo - Magazine of European medical oncology</jtitle><stitle>memo</stitle><date>2017-09-01</date><risdate>2017</risdate><volume>10</volume><issue>3</issue><spage>164</spage><epage>169</epage><pages>164-169</pages><issn>1865-5041</issn><eissn>1865-5076</eissn><abstract>Summary Acute lymphoblastic leukemia (ALL) forms a heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukemia, myeloid markers (CD13 and CD33) are frequent but CD117 is rare. On the other hand, the presence of multiple translocations is also associated with a higher or lower level of aberrant markers that could be effective in changing the prognosis of patients. Further studies are needed to confirm the relationship between aberrant expression with prognosis and response to treatment of ALL.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><doi>10.1007/s12254-017-0324-6</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1865-5041
ispartof Memo - Magazine of European medical oncology, 2017-09, Vol.10 (3), p.164-169
issn 1865-5041
1865-5076
language eng
recordid cdi_crossref_primary_10_1007_s12254_017_0324_6
source Springer Nature
subjects Medicine
Medicine & Public Health
Oncology
Review
title Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A22%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20aberrant%20expression%20of%20CD%20markers%20in%20acute%20lymphoblastic%20leukemia&rft.jtitle=Memo%20-%20Magazine%20of%20European%20medical%20oncology&rft.au=Kavianpour,%20Maria&rft.date=2017-09-01&rft.volume=10&rft.issue=3&rft.spage=164&rft.epage=169&rft.pages=164-169&rft.issn=1865-5041&rft.eissn=1865-5076&rft_id=info:doi/10.1007/s12254-017-0324-6&rft_dat=%3Ccrossref_sprin%3E10_1007_s12254_017_0324_6%3C/crossref_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c288t-1ad845a52b421eb440fa765f680489c4efe02ab932ad7871da3db132240d69203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true